Peyronie's disease (PD) is an inflammatory condition characterized by the formation of fibrous, noncompliant nodules in the tunica albuginea which can impede tunical expansion during penile erection, leading to deformity and bending. While the cause of this disease is thought to be due to microvascular trauma and abnormal wound healing, other hypotheses include genetic predisposition. In this review the pathophysiology of Peyronie's disease is discussed as well as current hypothese regarding its origin. Furthermore, there were significant associations between the risk factors for ED and PD, and with significant associations reported between PD and age, obesity, smoking, duration and number of cigarettes smoked per day. Dyslipidaemia, psychological disorders and the presence of at least one risk factor were significantly associated with PD. There were significant associations between a longer duration and poor metabolic control of diabetes and PD.
There is one medication approved by the Food and Drug Administration for the of Peyronie's disease. It's called collagenase Clostridium histolyticum (Xiaflex). The works by breaking down the buildup of collagen that causes penile curvature. It involves a series of in-office injections, directly into the penile lump, as well as penile modeling — brief exercises to gently stretch and straighten the penis. In clinical trials, this collagenase therapy significantly reduced curvature and bothersome symptoms associated with Peyronie's disease in many participants. Oral medication called pentoxifylline (Trental), verapamil (injections or topical gel) and interferon (injections).
Government is encouraging many projects regarding the cure and further detailed studies of the disease.
The disease’s prevalence was found to be 3.2% and appeared to increase with age. In a follow-up study of 97 men, 40% reported a worsening of their signs and symptoms over time. 47%, the disease had stabilized after resolution of the inflammatory process, and, in 13%, symptoms had even disappeared spontaneously. Rates were 74.3% in the treated group versus 50.0% in the placebo group. Major countries not treating PD were Italy, France, UK and Germany.
Efficacy and safety of low molecular weight heparin compared to unfractionated heparin for chronic outpatient hemodialysis in end stage renal disease: Systematic review and meta-analysis PPT Version |
Metalloproteinases and their inhibitors gene expression profiles in leukocytes of primary hypertension (PH), non-alcoholic fatty liver disease (NAFLD), and obese children PPT Version |
Depressive symptoms among older adults with mild to moderate Knee osteoarthritis are highly prevalent and are predicted by disease management self-efficacy: A cross-sectional study of depressive symptom prevalence, and clinical interrelationships PPT Version |
Tracking of viral evolution during an outbreak of emerging beak and feather disease virus (BFDV) infection in the critically endangered Orange-bellied parrot (Neophema chrysogaster) PPT Version |